GLP-1 Pill or Weekly Injection? Bioavailability, the 30-Minute Rule, Dose Equivalence, and What Oral Semaglutide and Orforglipron Mean for Microdosing

A woman eight months into a 0.15 mg weekly semaglutide protocol asks her prescriber whether she can move to a pill. She travels for work, hates carrying a pen through airport security, and has read that there is now a tablet without the empty-stomach rule. Her prescriber asks a question back: does she know that the smallest tablet of any oral GLP-1 product delivers more drug than she is currently taking? She did not. Most people do not, because the tablets have been sold on convenience and the arithmetic underneath them has not been widely explained.

The oral GLP-1 field changed twice in five months. Oral semaglutide at 25 mg was approved for weight management in December 2025 under the Wegovy name, adding to the Rybelsus tablets that had been available for type 2 diabetes since 2019. Orforglipron, a non-peptide small molecule from Eli Lilly, was approved on April 1, 2026 as Foundayo, the first GLP-1 tablet with no food, water, or timing restrictions. Both products now sit alongside the weekly injections, and people already on a low-dose injectable protocol are asking whether a tablet would do the same job.

This article works through the pharmacology in order: how a peptide survives the stomach at all, why the 30-minute rule exists and what breaking it costs, how the tablets compare with the injections in the trials that led to their approvals, what orforglipron's different chemistry changes, why tablets cannot be divided and what that means for anyone thinking in fractions of a milligram, how daily and weekly dosing differ in blood-level steadiness, and which questions belong in the conversation with a prescriber before any switch.

How does a peptide like semaglutide survive the stomach as a pill?

It mostly does not; oral semaglutide gets about 1 percent of its dose into the blood, and it manages even that only because each tablet carries 300 mg of an absorption enhancer called SNAC. Semaglutide is a 31-amino-acid peptide, and the stomach exists to break peptides apart with acid and pepsin. SNAC, or sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, dissolves alongside the semaglutide and raises the pH in the small pocket of stomach fluid around the eroding tablet. That local buffering protects the peptide from pepsin for long enough to cross the stomach lining, and SNAC also loosens the lining transiently to let it through. Buckley and colleagues showed in 2018 that absorption happens in the stomach itself, not further down the gut, and that a tablet which does not erode there delivers almost nothing.

The consequence is a dose scale that looks nothing like the injection. The Rybelsus label treats 14 mg oral once daily as comparable in exposure to 0.5 mg subcutaneous once weekly, and 7 mg oral daily as the step below. Fourteen milligrams a day is 98 mg a week, against 0.5 mg injected, so the tablet route uses roughly 200 times more semaglutide to reach the same blood level. The 25 mg tablet approved for weight management in 2025 uses 175 mg a week. This is not wasteful in any way that matters to the person taking it, since what is not absorbed is simply digested, but it explains why the tablets are large, why a second enhancer-free route was worth building, and why the manufacturing cost per dose is high.

Why does oral semaglutide have a 30-minute rule, and what happens if you break it?

The rule exists because absorption depends on the tablet eroding in a small, undisturbed pool of stomach fluid, and anything that dilutes or displaces that pool cuts the dose that gets through. The Rybelsus and oral Wegovy labels are specific: take the tablet on waking with no more than 4 ounces (about 120 mL) of plain water, and wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Baekdal and colleagues tested the conditions systematically in healthy volunteers. A post-dose fast of 15 minutes gave lower exposure than 30, and longer fasts gave more; a larger volume of water lowered exposure; and taking the tablet with or shortly after food reduced absorption to a small fraction of the fasted value. The label summarises the same finding in one line: taking the tablet with food or with a large volume of water reduces absorption.

The practical cost of the rule is that every morning requires the same 30-minute ritual, and the practical cost of breaking it is not a dangerous overdose but an unpredictable underdose. A person who takes the tablet with breakfast has taken very little semaglutide that day; a person who takes it with coffee has taken an unknown amount. Because semaglutide has a half-life of about a week, a single broken morning barely registers at steady state, but a habit of broken mornings produces a lower and more variable blood level than the dose on the box implies. The label also notes that other tablets swallowed at the same time can have their own absorption changed; the levothyroxine study in the Rybelsus label found a 33 percent rise in thyroid hormone exposure when the two were taken together.

How much weight loss do the pills produce compared with the injections?

At their maximum labelled doses the tablets land within a few percentage points of the 2.4 mg semaglutide injection and well short of tirzepatide. OASIS 4, published by Wharton and colleagues in 2025, randomised 307 adults with obesity or overweight to oral semaglutide 25 mg or placebo for 64 weeks; mean weight loss was 13.6 percent against 2.2 percent. OASIS 1, published by Knop and colleagues in 2023, tested the 50 mg tablet over 68 weeks and found 15.1 percent against 2.4 percent. The 2.4 mg weekly injection in STEP 1 produced 14.9 percent against 2.4 percent over 68 weeks. The three semaglutide results sit close together, which is what pharmacology predicts: the molecule is identical, and once exposure is matched the route stops mattering.

Orforglipron's trial, ATTAIN-1, published by Jastreboff and colleagues in 2025, randomised 3,127 adults with obesity or overweight to three doses or placebo for 72 weeks. Weight loss was 7.5 percent at 6 mg, 8.4 percent at 12 mg, and 12.4 percent at 36 mg, against 0.9 percent on placebo. The dose-response is real but shallow above 12 mg, and the top dose sits a little below the semaglutide tablets and injection. Tirzepatide 15 mg in SURMOUNT-1 produced 20.9 percent over 72 weeks, a figure no oral product has approached. None of these trials compared the products head to head, and their populations and durations differ, so the chart below is a map of where each landed, not a ranking.

What does orforglipron change, and how is it dosed?

Orforglipron removes the absorption problem entirely by not being a peptide. It is a small organic molecule that binds the GLP-1 receptor at a different site from the natural hormone, survives stomach acid and digestive enzymes on its own, and is absorbed through the gut wall without an enhancer. The Foundayo label, approved on April 1, 2026, allows the tablet at any time of day with or without food and water, which is the single largest practical difference from oral semaglutide. The other difference is speed: orforglipron's half-life is roughly 1.5 days rather than a week, so blood levels reach steady state in about a week after each dose change and fall away within days of stopping.

The labelled dosing does not match the trial dosing, which has caused confusion. ATTAIN-1 started everyone at 1 mg daily and stepped up every four weeks to maintenance doses of 6, 12, or 36 mg. The approved product uses a different formulation and different strengths: 0.8 mg to start, then 2.5 mg, then 5.5 mg, each held for at least 30 days, with maintenance options of 9, 14.5, or 17.2 mg and a maximum of 17.2 mg daily. The label's 17.2 mg corresponds in exposure to the trial's top arm; the numbers are simply expressed in different units of the active substance. Anyone reading a trial paper alongside a prescription should expect the milligram figures to disagree.

Side effects in ATTAIN-1 were the familiar gastrointestinal set, rising with dose. Nausea affected roughly 14 to 34 percent of people on orforglipron against about 10 percent on placebo, vomiting roughly 8 to 24 percent against 3 percent, and 5 to 10 percent discontinued for adverse events against under 3 percent on placebo. Those figures are in the same range as the semaglutide and tirzepatide trials. The pill does not spare the stomach; the stomach is responding to the receptor, and the receptor does not know how the drug arrived.

Can you microdose a GLP-1 pill?

Not below the smallest tablet, and no label permits splitting one. The Rybelsus, oral Wegovy, and Foundayo prescribing information each instruct that tablets be swallowed whole and not split, crushed, or chewed. For oral semaglutide the reason is mechanical: the tablet's erosion beside its SNAC in the stomach is what makes absorption possible, and a broken tablet changes the geometry and exposes the peptide before the enhancer has done its work. For orforglipron the label's instruction stands regardless of the pharmacology behind it. The lowest tablet is therefore the floor, and the floor is higher than most microdose protocols. Rybelsus's 3 mg starting tablet is 21 percent of its 14 mg maximum, and the label describes it as a tolerability step rather than an effective dose. Oral Wegovy's 1.5 mg is 6 percent of 25 mg. Foundayo's 0.8 mg is 4.7 percent of 17.2 mg.

Compare that with the injectable. A Wegovy pen's lowest click, 0.25 mg, is 10 percent of the 2.4 mg maximum. A vial of semaglutide drawn with an insulin syringe under a prescriber's direction can deliver 0.1 mg, which is 4 percent, or 0.05 mg, which is 2 percent, and can be adjusted in increments of a few hundredths of a milligram. That granularity is the whole basis of a microdosing protocol, and no tablet offers it. The woman in the opening example, on 0.15 mg weekly, was taking about 6 percent of the injectable maximum; the smallest Foundayo tablet would have moved her to roughly 5 percent of a different drug's maximum, the smallest oral Wegovy to 6 percent of semaglutide's oral maximum at 1 percent bioavailability, and the smallest Rybelsus to more than triple her current relative dose.

There is a second, subtler difference: the shape of the blood level over the week. Semaglutide's half-life is about a week whether swallowed or injected, so a weekly injection rises after each dose and falls roughly 25 to 30 percent by the day before the next one, while a daily tablet at matched exposure barely moves from one day to the next. Some people notice the injection's weekly rhythm in their appetite and in the clustering of nausea in the two or three days after a dose; a daily tablet flattens both. Orforglipron sits at the other extreme: with a half-life near 1.5 days, a daily tablet swings noticeably between morning and the next morning, closer in rhythm to a twice-weekly injection than to a weekly one. Steady state takes four to five weeks for semaglutide by either route and about a week for orforglipron, which is the window over which any change should be judged.

Which format suits which situation, and what should the prescriber hear first?

The tablet suits a person who wants a labelled dose, travels without refrigeration, and either can keep a strict morning routine (oral semaglutide) or wants none at all (orforglipron); the injectable vial suits a person whose protocol lives below the smallest tablet. The table below sets the three formats side by side on the points that decide most switches. None of the rows is a recommendation. The person in the opening example ended up staying on her vial, because the thing she wanted from a pill, freedom from the pen at airports, mattered less to her than the dose she had spent eight months finding.

The prescriber conversation has a natural order. First the current dose, stated as a fraction of the injectable maximum, so that both people can see whether the smallest tablet is a step up. Second the morning routine, honestly assessed: a person who drinks coffee on waking and takes a thyroid tablet at the same time has two conflicts with oral semaglutide before breakfast. Third the medication list, because oral semaglutide's 30-minute exclusion applies to every other tablet and its levothyroxine interaction is documented, while orforglipron's label carries its own interaction list that a pharmacist should check. Fourth the timescale: semaglutide by either route takes four to five weeks to settle, so a switch should be judged after a month. And fifth, the reason for switching. If it is the pen, a vial and syringe solves it. If it is the cold chain, a tablet does. If it is the hope of a gentler stomach, the trial data do not support that hope for any tablet at a matched dose.

The tablet solved the needle. It did not solve the fraction.

Oral semaglutide and orforglipron are real advances. One got a fragile peptide through the stomach at a 1 percent yield and made it work; the other rebuilt the drug as a small molecule and did away with the yield problem altogether. At their maximum doses both approach the strongest semaglutide injection, and neither spares the stomach on the way there. What neither product offers is the thing a microdosing protocol is built on: a dose that can be set, and held, well below the smallest unit a manufacturer chose to make. A tablet cannot be split; a vial can be drawn to a twentieth of a milligram. For a person whose protocol is a labelled dose, the pill is a legitimate route to it. For a person whose protocol is a fraction, the pill is a different protocol, and the prescriber should hear that framing before anyone opens a blister pack.

Frequently asked questions

Clinical references

1. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10(467):eaar7047.
2. Bækdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Søndergaard FL, Borregaard J. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. Diabetes Therapy. 2021;12(7):1915-1927.
3. Bækdal TA, Thomsen M, Kupčová V, Hansen CW, Anderson TW. Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study. Clinical Pharmacology in Drug Development. 2021;10(5):453-462.
4. Novo Nordisk. Rybelsus (semaglutide) tablets: prescribing information, including dosing instructions, comparability of 14 mg oral to 0.5 mg subcutaneous, tablet-splitting prohibition, and levothyroxine coadministration data. US Food and Drug Administration; 2019, with subsequent revisions.
5. Novo Nordisk. Wegovy (semaglutide) tablets: prescribing information for chronic weight management. US Food and Drug Administration; December 2025.
6. Eli Lilly. Foundayo (orforglipron) tablets: prescribing information, including dosing schedule (0.8 mg to 17.2 mg once daily) and administration without regard to food or water. US Food and Drug Administration; April 2026.
7. Wharton S, Blevins T, Connery L, et al. Oral semaglutide 25 mg in adults with overweight or obesity: the OASIS 4 randomised, placebo-controlled trial. New England Journal of Medicine. 2025.
8. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719.
9. Jastreboff AM, Kaplan LM, Frías JP, et al. Once-daily oral orforglipron for obesity: the ATTAIN-1 randomised trial. New England Journal of Medicine. 2025.
10. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine. 2023;389(10):877-888.
11. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
13. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.
14. Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical Pharmacokinetics. 2019;58(6):781-791.
15. Novo Nordisk. Wegovy (semaglutide) injection: prescribing information, dosing schedule 0.25 mg to 2.4 mg once weekly. US Food and Drug Administration; 2021, with subsequent revisions.